AcquisitionMar 2, 2026Terminated
🇺🇸 United States
CTCandid Therapeutics, Inc.RRallybio Corporation
Healthcare › Biotechnology
Deal valueUndisclosed
AnnouncedMar 2, 2026
ConsiderationStock
StructureOne-step merger
RegionNorth America
Cross-borderNo
Contingent paymentYes
Overview
Rallybio agreed to acquire Candid Therapeutics in an all-stock reverse merger, with the combined company to operate as Candid Therapeutics and trade as CDRX. The merger is accompanied by a concurrent private financing of over $505 million in Candid, and Rallybio stockholders receive CVRs tied to proceeds from legacy assets.
Deal rationale
The merger gives Candid a Nasdaq listing and, with the financing, funds its T-cell engager autoimmune pipeline through 2030, while Rallybio stockholders share in future value creation.
AI-generated from the SEC filingTerminatedHealthcare › BiotechnologyUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Stock |
Advisors
Buy-side
CCCitizens Capital Markets & AdvisoryEEvercore
Sell-side
None listed
Parties
Target
CTCandid Therapeutics, Inc.
- Headquarters
- United States
- Ticker
- —